News

11/18/2025 • Lysoway Announces Featured Talk at the 2026 Alzheimer’s & Parkinson’s Drug Development Summit
Cambridge, MA, November 17, 2025 – Lysoway Therapeutics is pleased to announce that Yongchang Qiu, Founder and CEO, has been invited to speak at the ... » Full Story
10/16/2025 • Lysoway showcases first-in-class TRPML1 agonist data and announces Phase I clinical plan at Michael J. Fox foundation’s PD Therapeutics Conference
Cambridge, MA, October 16, 2025 – Lysoway Therapeutics’ Senior Vice President and Head of Research and Translational Science, Valerie Cullen, PhD, today presented an invited talk and ... » Full Story
7/25/2025 • Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease
Cambridge, MA, July 25, 2025 – Lysoway Therapeutics, a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received ... » Full Story
4/8/2025 • Lysoway Therapeutics Presents New Preclinical Data for Its Brain-Penetrant TRPML1 Agonist at AD/PD™ 2025
Findings show improved lysosomal function, reduced inflammation, and neuroprotection in Alzheimer’s and Parkinson’s disease models Cambridge, MA, April 8, 2025 – Lysoway Therapeutics, a biotechnology ... » Full Story
5/30/2024 • Lysoway Therapeutics Inc. appoints Valerie Cullen, PhD as Senior Vice President and Head of Research and Translational Science
Cambridge, MA, May 30, 2024 – Lysoway Therapeutics, a leading discovery-stage biotech company dedicated to developing next-generation treatments for patients with neurodegenerative diseases, today proudly ... » Full Story
4/17/2024 • Lysoway Therapeutics appoints Chris Adams, PhD to its board of directors
Cambridge, MA, April 2, 2024 – Lysoway Therapeutics, a leading discovery-stage biotech company dedicated to developing next-generation treatments for patients with neurodegenerative diseases, today proudly ... » Full Story
1/5/2023 • Lysoway Therapeutics has received a research grant from the Silverstein Foundation to investigate the therapeutic potential of its lysosomal ion channel modulators in GBA-deficient Parkinson’s disease
Cambridge, MA and New York, NY, Jan. 5, 2023 – Lysoway Therapeutics, a startup biotech developing small molecule modulators of lysosomal ion channels and leader ... » Full Story
10/5/2022 • Lysoway Therapeutics has raised a total of $22m in Series A financing to advance novel therapies for neurodegenerative diseases and metabolic disorders
Lysoway Therapeutics, a Cambridge, MA based startup developing small molecule modulators of lysosomal ion channels, announced today raising a total of $22m in Series A ... » Full Story